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Summary
The type II and type III mutations at the FXI locus, which
cause coagulation factor XI deficiency, have high fre-
quencies in Jewish populations. The type III mutation
is largely restricted to Ashkenazi Jews, but the type II
mutation is observed at high frequency in both Ashke-
nazi and Iraqi Jews, suggesting the possibility that the
mutation appeared before the separation of these com-
munities. Here we report estimates of the ages of the
type II and type III mutations, based on the observed
distribution of allelic variants at a flanking microsatellite
marker (D4S171). The results are consistent with a re-
cent origin for the type III mutation but suggest that the
type II mutation appeared 1120 generations ago. This
finding demonstrates that the high frequency of the type
II mutation among Jews is independent of the demo-
graphic upheavals among Ashkenazi Jews in the 16th
and 17th centuries.
Introduction
Coagulation factor XI deficiency results from mutations
at the FXI gene located on chromosome 4. The disease
is common in Ashkenazi Jews, present to a lesser degree
among other Jews, and occurs only rarely in non-Jewish
populations (Seligsohn 1978; Saito et al. 1985; Bolton-
Maggs et al. 1992). Four distinct mutations are observed
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in Jewish populations, with types II and III by far the
most frequent. The type III mutation, caused by a mis-
sense change at position 283, has an allele frequency of
2.54% in Ashkenazi Jews but has not been observed in
large samples of Iraqi and Sephardic Jews (Shpilberg et
al. 1995; Peretz et al. 1997). The type II mutation,
caused by a nonsense change at position 117, has a fre-
quency of 2.17% in Ashkenazi Jews, occurs with a fre-
quency of 1.67% in Iraqi Jews, and is present at lower
frequencies in other Jewish populations. A common
founder for this mutation has been indicated by the pres-
ence of a single background haplotype among both Ash-
kenazi and Iraqi Jews (Peretz et al. 1997). Of the many
single-locus disorders with high frequency among Jews,
the type II factor XI mutation is the first to be reported
with high frequency in both Ashkenazi and non-Ash-
kenazi Jewish populations. The origin of Iraqi Jewry is
controversial, but it has been argued that it derives from
the Babylonian exile, 12,500 years ago. According to
this view, the type II mutation may have occurred within
the ancestral Jewish population, before the Babylonian
exile and well before the dispersion after the Bar Kochba
revolt against the Romans (132–135 A.D.). The type III
mutation, being restricted to Ashkenazi Jews, is sug-
gested to have arisen sometime after the emergence of
Ashkenazi Jews and in substantial isolation from Iraqi
Jews (Shpilberg et al. 1995). To test these predictions,
we used the observed distribution of allelic variants of
a flanking microsatellite marker (D4S171) on mutant
and control backgrounds to estimate the age of each
mutation (Reich and Goldstein, in press; Stephens et al.
1998).
Data and Analysis
When a new mutation appears, it occurs on a single
chromosome and thereby generates linkage disequilib-
rium with any polymorphic markers. The rate at which
this disequilibrium breaks down depends on the recom-
bination and mutation rates; hence, if estimates of these
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Table 1
Frequencies of Alleles at the Marker Locus D4S171 in Affected and
Control Chromosomes
ALLELE
SIZE
(BP)
FREQUENCY
CEPHa
Control
( )n  103
Type II
( )n  99
Type III
( )n  73
143 .01 .02 .00 .00
145 .01 .03 .03 .26
147 .09 .06 .02 .05
149 .04 .08 .02 .01
151 .34 .38 .48 .52
153 .39 .22 .27 .10
155 .08 .12 .06 .01
157 .02 .00 .02 .01
159 .00 .05 .07 .01
161 .01 .00 .01 .00
163 .00 .02 .01 .00
165 .00 .03 .00 .01
a Data provided by James Weber.
are available, the observed level of disequilibrium can
be used to estimate the date of the mutation (Risch et
al. 1995; Stephens et al. 1998). To achieve statistical
power, however, it is important to use a marker at an
appropriate recombinational distance—that is, great
enough to ensure the generation of nonancestral hap-
lotypes at moderate frequency but, ideally, not so great
as to equilibrate allele frequencies within the time frame
of interest. Of 74 informative meioses, we observed a
single recombination event between FXI andD4S171 (a
dinucleotide microsatellite), implying a recombination
rate of .0135, appropriate for estimating coalescent
times on the order of hundreds of generations. Fre-
quencies of alleles at this marker were determined in 99
chromosomes carrying the type II mutation and in 73
chromosomes carrying the type III mutation. We also
characterized 103 chromosomes from healthyAshkenazi
Jews, to estimate the proportion of recombination events
that are expected to result in a nonancestral haplotype
(table 1).
In their study of idiopathic torsion dystonia, Risch et
al. (1995) used a method for estimating the coalescent
time (G) of mutant chromosomes that focuses on the
proportion of lineages not having undergone a mutation
or recombination event. If no regeneration of ancestral
haplotypes is assumed, the expected proportion of an-
cestral haplotypes is effectively , where G is theGrp  e
number of generations since the coalescence of the sam-
pled chromosomes and r is the effective mutation and
recombination rate (see eq. [1]). When there is a mod-
erate to high proportion of nonancestral alleles among
the mutant chromosomes, however, it is necessary to
model the regeneration of ancestral haplotypes by the
recombination process. This can be done in a number
of ways, but we favor the Markov model representation
of Reich and Goldstein (in press) for its flexibility. Under
this formulation, it is straightforward to include an ar-
bitrary number of markers and both recombination and
mutation.
The full behavior of the system is easily represented
as a Markov process in which the state space is the
proportion of chromosomes in the ancestral and non-
ancestral categories, and the transition matrix K gives
the probabilities that each haplotype will be transformed
into the other in a single generation (Stephens et al.
1998; Reich and Goldstein, in press). The transition ma-
trix K is given by:
K  cR uM (1 c u)I , (1)
where c and u are scalars reflecting the recombination
and mutation rates, respectively. In this case, u 
(Weber and Wong 1993) and . The.00056 c  .0135
matrices R and M reflect the probabilities of producing
nonancestral haplotypes should a recombination or mu-
tation event occur, whereas I is the identity matrix. If a
represents the frequency of the ancestral allele in the
control population, the matrix R has the elements
, , , and . For-R  a R  a R  1 a R  1 a11 12 21 22
mally, M would depend on the frequencies of marker
alleles on mutant chromosomes, requiring a larger state
space than ancestral/nonancestral alleles. In our case,
however, because the recombination rate is much greater
than the mutation rate, we assume that the distribution
of allele sizes on mutant chromosomes matches that seen
in the control population. For simplicity, we also assume
a strict stepwise mutation model (Goldstein and Pollock
1997). Under these assumptions, M has the elements
, , , and ,M  0 M  b/2 M  1 M  1 b/211 12 21 22
where b is the frequency of all one-mutant neighbors of
the ancestral allele in the control population.
With the parameters ofK specified, the coalescent time
is estimated by multiplying the state vector by K itera-
tively until the observed proportion of ancestral hap-
lotypes is reached. Iteration begins at a frequency vector
of (1,0), corresponding to a starting point of only an-
cestral haplotypes. The analysis requires identification
of the ancestral allele, which cannot be determined with
certainty when the frequency of the nonancestral type
is moderately high, as is the case for both the type II
and type III mutations. For the type II mutation, the
data are consistent with the ancestral haplotype having
carried either the 151- or 153-bp allele, which is con-
sistent with the high frequency of these alleles in the
control population. If the 151-bp allele is assumed to
have been ancestral, the proportion of ancestral hap-
lotypes among mutant chromosomes (p) is .48, and the
frequency of the ancestral allele in the control population
(a) is .38, leading to an estimated coalescent time of 120
generations. If the 153-bp allele is assumed to have been
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ancestral, and , and the estimated coa-p  .27 a  .22
lescent time is 189 generations.
The analysis of the type III mutation is complicated
by the bimodal frequency distribution among themutant
chromosomes of an allele (145 bp) that is in low fre-
quency in the control populations. In theory, this dis-
crepancy could be caused by any of four factors: (1)
multiple origins for the type III mutation; (2) frequencies
of the allele in the control population being nonrepre-
sentative of those in the population in which the mutant
chromosomes have been recombining; (3) the mutation
having occurred originally on the 145-bp allele, despite
its rarity in the population; or (4) the occurrence, very
early after the appearance of the mutation, of a recom-
bination event between the chromosomes carrying 145-
and 151-bp alleles or, equivalently, of a multistep mu-
tation between these alleles. The first explanation is ruled
out by the observation of Peretz et al. (1997) that the
type III mutation is associated with a single, rare hap-
lotype defined by four closely linked markers. The sec-
ond explanation also appears unlikely because of the
similarity of marker allele frequencies in the Ashkenazi
control chromosomes and the CEPH chromosomes (ta-
ble 1). Although distinguishing the latter two explana-
tions would require more detailed information about the
genealogy than is available, we favor the fourth expla-
nation, because it is consistent with the substantially
larger differential between the 151- and 153-bp alleles
among mutant chromosomes than is observed in the
control population. If we accept this explanation, we
need not be concerned with whether the mutation ac-
tually occurred on a chromosome carrying a 145- or
151-bp allele, but rather we can treat both alleles col-
lectively as ancestral, yielding and andp  .78 a  .41
leading to an estimated coalescent time of 31 genera-
tions. Of course, the coalescent time for the true ances-
tral haplotype must be longer than this estimate. If we
treat the mutation as having occurred singly on either
the 145- or 151-bp allele, the estimated age of the mu-
tation would be 1100 generations.
Although the expected coalescent times are indepen-
dent of the shape of the genealogy, confidence intervals
are strongly dependent on the precise shape. One ap-
proach to the estimation of confidence intervals is to
carry out coalescent simulations assuming a range of
population growth rates, resulting in gene genealogies
ranging from the highly correlated trees typical of con-
stant population size to the star-shaped genealogies typ-
ical of very rapid growth. When the data provide
information on the number of recombination and mu-
tation events responsible for the observed nonancestral
haplotypes, it is possible to select, at least roughly,
among these types of genealogies to construct confidence
intervals (Reich and Goldstein, in press). Our data set,
however, provides relatively little information about the
shape of the genealogy, because of the combination of
a single marker locus and high frequencies of nonan-
cestral haplotypes. We therefore use a simple heuristic
argument to provide a rough guide to the degree of con-
fidence in these estimates, under different assumptions
concerning the gene genealogy. For convenience, we shall
use the term “confidence interval,” but it is important
to appreciate that these calculations are meant to be
illustrative of how genealogic shape influences confi-
dence and cannot be construed as formal confidence
intervals.
First, we assume a star genealogy in which all lineages
are uncorrelated—that is, lineages trace their ancestries
independently back to the root of the genealogy. In this
case, where n is the number of sampled chromosomes
and p is the proportion of ancestral chromosomes, there
are n independent observations of the time that has
elapsed since the appearance of the common ancestor
of the sample. In the case of the type II mutation, n 
, , and the confidence interval for the number99 p  .48
of ancestral chromosomes observed can be estimated as
2# the SD of a binomial distribution with parameters
.48 and 99, leading to a confidence interval for p of
.38–.58. When we apply the recursion in equation (1)
to this range, the confidence interval becomes 75–254
generations. A similar calculation for the case of the 153-
bp allele having been ancestral leads to a lower bound
on the age of the mutation of ∼120 generations. An
upper bound does not exist in this case, because the
lower bound on p is below the equilibrium frequency
set by the observed frequency of the ancestral allele in
the control population.
The conceptual basis of our approach for assessing
confidence intervals in a correlated tree depends on es-
timating an effective number of lineages that would re-
sult in an uncorrelated tree with properties similar to
those of a correlated tree with a greater number of sam-
pled chromosomes; that is, we assess the extent to which
correlations between lineages in the tree reduce the num-
ber of independent observations of the time to the com-
mon ancestor. To estimate the effective number of lin-
eages, we determine how many independent lineages
would be required to produce a match between the mu-
tant and control chromosome marker allele frequencies
at least as close as was actually observed. For example,
in the case of the type II mutation, !14 independent
lineages would have a !5% chance of leading to a match
that is as close as was actually observed.
To better understand the argument, imagine a gene-
alogy in which every chromosome is included within a
set of 10 exact copies, but each of these sets traces its
ancestry independently to the time of origin. In this case,
the number of independent lineages would be 10; how-
ever, we would not expect to have an allele-frequency
distribution that matches the control distribution as
1074 Am. J. Hum. Genet. 64:1071–1075, 1999
closely as does the observed distribution. That point is
reached only when there are at least 14 independent
lineages. Therefore, if we take 14 as the lower bound
on the “effective number” of lineages, the youngest pos-
sible ages for the type II mutation become 34 and 72
generations for the mutation having occurred on chro-
mosomes carrying the 151- and 153-bp alleles, respec-
tively. In the case of 14 lineages, there is no upper bound
on the coalescent time, because the lower bound on p
is below the equilibrium value. Applying a similar logic
to the type III mutation, we obtain 23 effective lineages,
and if we treat both the 145- and 151-bp alleles as an-
cestral, the estimated confidence interval is 5–70
generations.
This analysis considers uncertainty resulting from the
evolutionary process but ignores uncertainty in our es-
timation of the mutation and recombination rates. Fi-
nally, we note that the approach taken here estimates
the coalescent time of affected chromosomes, as opposed
to the time at which the mutation first appeared, which
must predate the coalescent time. Accurate estimation
of the date of the mutation would require detailed in-
formation about the population’s demography at the
time of the mutation (see Slatkin and Rannala 1997).
Discussion
The Ashkenazi Jewish population carries a range of
single-locus genetic diseases in high frequency (Good-
man 1978), and some authors have attributed this to
the demographic upheavals thought to have occurred
during and shortly after the 16th and 17th centuries
(Risch et al. 1995). The factor XI type II mutation, how-
ever, has a high frequency in both Iraqi and Ashkenazi
Jews. Coupling this observation with the demonstration
here that the mutation is old and probably predates the
separation of Ashkenazi and Iraqi Jews lends credence
to the hypothesis that the frequency of the factor XI type
II mutation is largely independent of the recent demo-
graphic upheavals particular to the Ashkenazi Jewish
population. The frequency of the type II mutation, there-
fore, seems to require other explanations. Genetic drift
in a population ancestral to the major Jewish groups
remains a possibility, as does positive selection on het-
erozygotes. These possibilities may ultimately be distin-
guishable by comparison of the shape of the genealogy
of affected chromosomes with those of the genealogies
of apparently neutral genomic regions. Although the se-
verity of the injury-related bleeding phenotype associ-
ated with factor XI deficiency depends on nutritional
status and the strength of selection against affected in-
dividuals is therefore unclear, this analysis suggests the
possibility that the frequencies of other genetic disorders
common in Ashkenazi Jews may also have little or noth-
ing to do with recent genetic drift in that community.
Similar genealogic analyses of other mutations should
help to elucidate the forces responsible for their presence
in the Ashkenazi population.
Since the best estimate for the coalescent time of the
type II mutation is 120 or 185 generations, depending
on which allele was ancestral, this analysis also provides
evidence that the ancestry of at least some members of
both the Iraqi and Ashkenazi Jewish populations can,
in fact, be traced to a single ancestral population, pre-
sumably residing in the kingdoms of Israel and Judah
before the various dispersions. Our findings on the dis-
tribution and age of the type II mutation, therefore, mir-
ror recent work on the distribution of the Y chromo-
somal haplotype characteristic of the Jewish priesthood
(Thomas et al. 1998). This haplotype, termed the “Co-
hen modal haplotype” (CMH), has a very high fre-
quency among self-designated members of the Jewish
priesthood and is also found at moderate frequency in
lay members of both Sephardic and Ashkenazi Jewry.
The CMH, however, has rarely been observed in non-
Jewish populations. Finally, whereas the estimation of
the age of the factor XI type III mutation is complicated
by the unlikely frequency distribution on the mutant
chromosomes, this distribution nevertheless appears
consistent with a relatively recent origin for that
mutation.
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